SRPT241220C137000
- 0.00
- 0.000.00%
Sarepta Therapeutics Newsroom
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Mizuho Securities Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Sell Rating on Sarepta Therapeutics Due to Limited LGMD Market Potential and Overestimated Elevidys Projections
Sarepta Therapeutics Analyst Ratings
Sarepta Therapeutics Analyst Ratings
Sarepta Therapeutics Is Maintained at Sell by HC Wainwright & Co.
H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Cuts Target Price to $75
Sarepta Therapeutics: Sell Rating Amid Uncertain Pipeline and Financial Risks
BMO Capital Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $200
Sarepta Therapeutics: Strong Buy Rating Amid Strategic Partnership and Promising Growth Potential
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $182 to $215
RBC Capital Remains a Buy on Sarepta Therapeutics (SRPT)
Sarepta Therapeutics Is Maintained at Overweight by Piper Sandler
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $182 to $217
Sarepta Therapeutics (SRPT) Gets a Buy From TD Cowen
Sarepta Therapeutics Analyst Ratings
Sarepta Therapeutics Receives Buy Rating From Gil Blum: Strategic Partnerships and Financial Stability Highlight Growth Potential
Sarepta Therapeutics: Strategic Expansion and Robust Pipeline Justify Buy Rating and $217 Price Target
Sarepta Therapeutics' Strategic Partnership With Arrowhead Signals Strong Growth Prospects: A Buy Recommendation
Oppenheimer Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)